Version 1
: Received: 11 September 2023 / Approved: 12 September 2023 / Online: 14 September 2023 (04:55:17 CEST)
How to cite:
Almási, K.; Kránitz, N.; Kullmann, T. Mosaic Neuroendocrine-/Adenocarcinoma of the Prostate: Clinical and Histological Description. Preprints2023, 2023090936. https://doi.org/10.20944/preprints202309.0936.v1
Almási, K.; Kránitz, N.; Kullmann, T. Mosaic Neuroendocrine-/Adenocarcinoma of the Prostate: Clinical and Histological Description. Preprints 2023, 2023090936. https://doi.org/10.20944/preprints202309.0936.v1
Almási, K.; Kránitz, N.; Kullmann, T. Mosaic Neuroendocrine-/Adenocarcinoma of the Prostate: Clinical and Histological Description. Preprints2023, 2023090936. https://doi.org/10.20944/preprints202309.0936.v1
APA Style
Almási, K., Kránitz, N., & Kullmann, T. (2023). Mosaic Neuroendocrine-/Adenocarcinoma of the Prostate: Clinical and Histological Description. Preprints. https://doi.org/10.20944/preprints202309.0936.v1
Chicago/Turabian Style
Almási, K., Noémi Kránitz and Tamás Kullmann. 2023 "Mosaic Neuroendocrine-/Adenocarcinoma of the Prostate: Clinical and Histological Description" Preprints. https://doi.org/10.20944/preprints202309.0936.v1
Abstract
Background: Mosaic cancers are composed of two or several genetically different cell populations. Mosaicism has been considered to be rare among malignancies, with the exception of the germ cell tumours. Although it has been described that neuroendocrine foci may be present within an adenocarcinoma of the prostate, this was ment for advanced stage disease and the clinical relevance of the histological finding has not been clarified. Patients and methods: We recently published the analysis of a small cohort of patients who had neuroendocrine cancer of the prostate. Contrarily to the general assumption of a rare disease with poor prognosis, the incidence was found to be 2%, being 50 fold higher than the earlier data. During the follow-up the overall survival of some metastatic patients reached several years. The particularity of patients with favourable outcome was the parallel elevation of PSA and NSE. They received anticancer treatments in an alternating way directed according to the tumour marker that was in rise. The aim of this paper is to show the pathological background of our clinical observations. Results: Histological images of de novo mosaic prostate cancers are shown. A model explaining the development of mosaic prostate cancers is presented. The hypothesis of mosaicism within adenocarcinomas is formulated in addition. Conclusion: Mosaic neuroendocrine-/adenocarcinoma of the prostate is underestimated regarding its incidence as well as its prognosis.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
